Latest Clinical trial Stories
WCCT Global, a contract research organization headquartered in Southern California, has been awarded the 2013 Cypress Award. Costa Mesa, CA (PRWEB) May 08, 2013 Contract research organization WCCT Global has been awarded the 2013 Cypress Award for the second consecutive year. This has been awarded due to research work that WCCT Global has conducted over the past year and the growth within the organization. For 2013, only 1.4% of all who received this award have received this for two...
Medrio proudly announces Provonix to join the Medrio Partner Program. San Francisco, CA and Mullica Hill, NJ (PRWEB) May 08, 2013 Provonix, a customer-focused CRO providing innovative clinical trial solutions for pharmaceutical, biotechnology, and medical device companies, today joined the Medrio Partner Program after earning accreditation in Medrio’s eClinical Software as a Software (SaaS) platform. The Medrio Partner Program is a collaborative effort aligning Medrio resources with...
REDWOOD CITY, Calif., May 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2013. "We continue to make progress in clinical development of our product candidates. We presented additional data at the recent American Society of...
Brett Smith for redOrbit.com - Your Universe Online Pharmaceutical Baxter International said it was ending late-stage trials for Gammagard, a once-promising treatment for Alzheimer’s disease, due to ineffective results. "The study missed its primary endpoints," Ludwig Hantson, Baxter's head of bioscience said in a statement to AFP. "We are currently re-evaluating our approach," he told reporters. “There is a lot of hypothesis but there are a lot of question marks here as well.”...
-Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring - Application of Joint Frailty Model- SAN DIEGO, May 8, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for the MYDICAR development program at an upcoming Conference. The conference "Statisticians in the Pharmaceutical...
-- Arena to Receive $65 Million in Milestone Payments from Eisai -- SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ( )(pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal...
ST. HELIER, Jersey, May 7, 2013 /PRNewswire/ -- Novocure announced today that the EF-14 pivotal clinical trial for patients with newly diagnosed glioblastoma (GBM) brain tumors has enrolled its first patient in Korea. This randomized, controlled trial is designed to enroll approximately 700 patients and will test the efficacy and safety of NovoTTF(TM) Therapy when added to the current best standard of care for newly diagnosed GBM. NovoTTF Therapy is delivered by a portable,...
SOUTH SAN FRANCISCO, Calif., May 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively....
LONDON, May 7, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces that it has received commercialization approval for its prescription medicine Sativex(®) in Italy. A full marketing authorization has been granted by the authorities in Italy for the treatment of moderate to severe...
Diagnostics Research Group is seeking individuals with osteoarthritis for an upcoming study. (PRWEB) May 06, 2013 Diagnostics Research Group, an independent site for pharmaceutical and device research, is working with pharmaceutical companies to assess osteoarthritis (OA) medications currently not available to the public. Osteoarthritis is the most common form of arthritis and affects an estimated 27 million Americans. OA occurs when a joint’s cartilage breaks down. The absence of...
